Insulin Market Scope And Analysis

  • Report Code : TIPRE00004051
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 186
Buy Now

Insulin Market Analysis and Scope (2023 to 2028)

Buy Now

Insulin Market Report Insulin Market Size and Share Insulin Market Scope and Analysis

Insulin Market Report Scope

Report Attribute Details
Market size in 2022 US$ 60.18 Billion
Market Size by 2028 US$ 111.21 Billion
Global CAGR (2022 - 2028) 10.8%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By Type
  • Long Acting Insulin
  • Rapid Acting Insulins
  • Short acting Insulins and Traditional Human Insulins
  • Concentrated Insulins and Combination Insulins
  • Biosimilar Insulins
  • Glucagon-like peptide-1
  • Pens and Needles
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Eli Lily and Company
  • Novo NordiskA S
  • Biocon
  • Wockhardt
  • Adocia
  • GlaxoSmitheKline plc
  • Sanofi
  • Pfizer
  • Merck Co Inc

    • Recent Developments:

    Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the insulin market. A few recent key market developments are listed below: 

    • In Jun 2022, Sanofi and Health2Sync have signed a partnership to bring digital solutions for insulin management to Japan. Both the companies will jointly develop digitized features on insulin in Japan such as connected caps for insulin and titration alerts.
    • In Jun 2022, Sanofi announced that the company would cap the monthly price of its insulin for uninsured Americans at US$ 35, down from US$ 99. The company will be commercializing the insulins such as Lantus Insulin Glargine U-100, Toujeo, Admelog, and Apidra for the uninsured at US$35 for a 30-day supply.
    • In Jan 2022, Merck announced an extension to the label for metformin products in EU such as Glucophage, Glucophage XR, and Stagid for use throughout the pregnancy.